Welltica+ on MSN
Experts call for changes to ADHD treatment after new research
Experts are calling for changes to ADHD care as new research raises questions about medication safety.
The US FDA has accepted for priority review Otsuka Pharmaceutical’s NDA submitted for centanafadine, an investigational, once-daily extended-release capsule for ADHD treatment.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results